Sergey Ryazanov

General Motors (Germany) — Germany

Medicine · Health Sciences

20h-index1.8kcitations51works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(20), Parkinson's Disease Mechanisms and Treatments(18), Cholinesterase and Neurodegenerative Diseases(8), Neurological disorders and treatments(6), Computational Drug Discovery Methods(5)

Publications51 total

[11C]MODAG 005 – a PET tracer targeting alpha-synuclein aggregates in the brain
2025Open Access
Anle138b binds predominantly to the central cavity in lipidic Aβ₄₀ fibrils and modulates fibril formation
Nature Communications·2025· 1 citedOpen Access
The clinical drug candidate anle138b binds predominantly to the central cavity in lipidic Aβ₄₀ fibrils and modulates fibril formation.
2025Open Access
The clinical drug candidate anle138b binds predominantly to the central cavity in lipidic Aβ₄₀ fibrils and modulates fibril formation
2025Open Access
The oligomer modulator molecule anle138b ameliorates Huntington’s disease phenotypes in vivo
Annals of Anatomy - Anatomischer Anzeiger·2025
Structural insight into binding of novel PET tracer MODAG-005 to lipidic <i>α</i> -Synuclein fibrils
2025Open Access
Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington’s disease
2025Open Access
The amyloid oligomer modulator anle138b has disease modifying effects in a human IAPP transgenic mouse model of type 2 diabetes mellitus (hIAPP Ob/Ob mice)
2024· 1 citedOpen Access
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins
Melanoma Research·2024· 5 citedOpen Access
[11C]MODAG 005 – a novel PET tracer targeting alpha-synuclein aggregates in the brain
2024· 6 citedOpen Access
Development and Radiosynthesis of [11C]MODAG-005 for in vivo Imaging of alpha-synuclein Pathology
Nuclear Medicine and Biology·2023· 1 cited
Anle138b interaction in α-synuclein aggregates by dynamic nuclear polarization NMR
Methods·2023· 15 citedOpen Access
Discovery of [11C]MODAG-005, a novel PET tracer targeting alpha-synuclein aggregates
Nuklearmedizin - NuclearMedicine·2023· 1 cited
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
Nature Communications·2022· 50 citedOpen Access
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial
EBioMedicine·2022· 79 citedOpen Access
Urban Growth and City Police in the Urals in the Late 19th – Early 20th Century
Technologos·2022Open Access
[C-11]MODAG-001-towards a PET tracer targeting alpha-synuclein aggregates
European Journal of Nuclear Medicine and Molecular Imaging·2021· 3 cited
[11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates
European Journal of Nuclear Medicine and Molecular Imaging·2020· 90 citedOpen Access
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
Translational Neurodegeneration·2020· 35 citedOpen Access
Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization
Scientific Reports·2020· 49 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Christian Griesinger(48), Andrei Leonov(45), Armin Giese(35), Felix Schmidt(13), Johannes Levin(12), Armin Giese(10), Daniel Weckbecker(9), Stefan Becker(9), Kristina Herfert(8), Loren B. Andreas(8), Laura Kuebler(7), Sabrina Buss(7), Andreas Maurer(7), Daniel Bleher(7), Karin Giller(7), Viktoria Ruf(6), Bernd J. Pichler(6), Jens A. Wagner(5), Catharina Prix(5), Markus Zweckstetter(5)